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Summary
Background The 2014 west African Zaire Ebola virus epidemic prompted worldwide partners to accelerate clinical 
development of replication-defective chimpanzee adenovirus 3 vector vaccine expressing Zaire Ebola virus 
glycoprotein (ChAd3-EBO-Z). We aimed to investigate the safety, tolerability, and immunogenicity of ChAd3-EBO-Z 
in Malian and US adults, and assess the eﬀ ect of boosting of Malians with modiﬁ ed vaccinia Ankara expressing Zaire 
Ebola virus glycoprotein and other ﬁ lovirus antigens (MVA-BN-Filo). 
Methods In the phase 1, single-blind, randomised trial of ChAd3-EBO-Z in the USA, we recruited adults aged 
18–65 years from the University of Maryland medical community and the Baltimore community. In the phase 1b, 
open-label and double-blind, dose-escalation trial of ChAd3-EBO-Z in Mali, we recruited adults 18–50 years of age 
from six hospitals and health centres in Bamako (Mali), some of whom were also eligible for a nested, randomised, 
double-blind, placebo-controlled trial of MVA-BN-Filo. For randomised segments of the Malian trial and for the US 
trial, we randomly allocated participants (1:1; block size of six [Malian] or four [US]; ARB produced computer-
generated randomisation lists; clinical staﬀ  did randomisation) to diﬀ erent single doses of intramuscular 
immunisation with ChAd3-EBO-Z: Malians received 1 × 10¹⁰ viral particle units (pu), 2·5 × 10¹⁰ pu, 5 × 10¹⁰ pu, or 
1 × 10¹¹ pu; US participants received 1 × 10¹⁰ pu or 1 × 10¹¹ pu. We randomly allocated Malians in the nested trial (1:1) 
to receive a single dose of 2 × 10⁸ plaque-forming units of MVA-BN-Filo or saline placebo. In the double-blind 
segments of the Malian trial, investigators, clinical staﬀ , participants, and immunology laboratory staﬀ  were masked, 
but the study pharmacist (MK), vaccine administrator, and study statistician (ARB) were unmasked. In the US trial, 
investigators were not masked, but participants were. Analyses were per protocol. The primary outcome was safety, 
measured with occurrence of adverse events for 7 days after vaccination. Both trials are registered with ClinicalTrials.
gov, numbers NCT02231866 (US) and NCT02267109 (Malian).
Findings Between Oct 8, 2014, and Feb 16, 2015, we randomly allocated 91 participants in Mali (ten [11%] to 
1 × 10¹⁰ pu, 35 [38%] to 2·5 × 10¹⁰ pu, 35 [38%] to 5 × 10¹⁰ pu, and 11 [12%] to 1 × 10¹¹ pu) and 20 in the USA (ten 
[50%] to 1 × 10¹⁰ pu and ten [50%] to 1 × 10¹¹ pu), and boosted 52 Malians with MVA-BN-Filo (27 [52%]) or saline 
(25 [48%]). We identiﬁ ed no safety concerns with either vaccine: seven (8%) of 91 participants in Mali (ﬁ ve [5%] 
received 5 × 10¹⁰ and two [2%] received 1 × 10¹¹ pu) and four (20%) of 20 in the USA (all received 1 × 10¹¹ pu) given 
ChAd3-EBO-Z had fever lasting for less than 24 h, and 15 (56%) of 27 Malians boosted with MVA-BN-Filo had 
injection-site pain or tenderness.
Interpretation 1 × 10¹¹ pu single-dose ChAd3-EBO-Z could suﬃ  ce for phase 3 eﬃ  cacy trials of ring-vaccination 
containment needing short-term, high-level protection to interrupt transmission. MVA-BN-Filo boosting, although a 
complex regimen, could confer long-lived protection if needed (eg, for health-care workers).
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and Infectious Diseases.
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Introduction
By August 2014, the burgeoning west African Zaire Ebola 
virus epidemic, which began in rural Guinea and spread 
to adjacent Liberia and Sierra Leone,1 was accelerated by 
transmission in crowded urban slums. Health-care and 
other front-line workers accounted for about 5–10% of 
deaths, and ensuing absenteeism weakened curative and 
preventive services.2,3 Absence of licensed anti-Ebola 
virus treatments or vaccines to combat the epidemic 
contributed to a public health calamity in the world’s 
least developed region.4 A glimmer of hope came from 
two Ebola vaccines in development that protected non-
human primates (NHPs) against lethal challenge with 
Ebola virus.5–8 One vaccine, based on a replication-
defective chimpanzee adenovirus 3 vector expressing 
Zaire Ebola virus glycoprotein (ChAd3-EBO-Z),9 had 
never been given to human beings.
In this report, we describe the accelerated clinical 
development programme that investigated the safety, 
tolerability, and immunogenicity of ChAd3-EBO-Z at 
four diﬀ erent doses in Malian adults and two diﬀ erent 
doses in US adults. Because ﬁ ndings from studies9 in 
NHPs have shown that both immunogenicity and 
duration of high-level protection against challenge can 
be extended by administration of a dose of modiﬁ ed 
vaccinia Ankara (MVA)-encoding Zaire Ebola virus 
glycoprotein, we sought to assess a heterologous booster 
in humans primed with ChAd3-EBO-Z. We therefore 
also describe the eﬀ ect of boosting of Malians with a 
heterologous vector, MVA expressing Zaire Ebola virus 
glycoprotein and other ﬁ lovirus antigens (MVA-BN-Filo).
Methods
Study design and participants
A phase 1b, open-label and double-blind, dose-escalation 
trial of ChAd3-EBO-Z was initiated at the Center for 
Vaccine Development (CVD)–Mali, Bamako, Mali, in 
adults 18–50 years of age, recruited from six hospitals 
and health centres. A phase 1, single-blind, randomised 
trial of ChAd3-EBO-Z was also initiated at the CVD in 
Baltimore, Maryland, USA, in participants aged 
18–65 years, recruited from the University of Maryland 
medical community and the Baltimore community. Full 
inclusion and exclusion criteria are listed in the appendix. 
Research in context
Evidence before this study
The outbreak of Zaire Ebola virus disease in west Africa in 
2014–15 was unparalleled in the morbidity and mortality 
burden that it evoked, its involvement of health-care and 
front-line workers, and the intensive transmission documented 
within urban slums and rural populations. Stakeholder 
meetings at WHO in August and September, 2014, concluded 
that clinical development of candidate vaccines to prevent 
Ebola virus disease should be accelerated. As of mid-August, 
2014, one promising candidate, replication-defective 
chimpanzee adenovirus 3 vector expressing Zaire Ebola virus 
glycoprotein (ChAd3-EBO-Z), which highly protected 
non-human primates (NHPs) against lethal challenge with 
virulent Ebola virus, had not yet been given to human beings. 
On Aug 30, 2014, and again on July 31, 2015, we searched 
PubMed for publications (no language or date restrictions) 
using various combinations of the terms “Ebolavirus”, “vaccine”, 
“Ebola”, “clinical trials”, “phase 1 clinical trials”, “non-human-
primates”, “non-clinical trials”, “chimpanzee adenovirus”, 
“adenovirus vector vaccines”, and “Modiﬁ ed Vaccinia Ankara 
vector”. We focused on studies published since 1995, but 
included older reports where relevant. As of July 31, 2015, only 
two clinical trials had been published of ChAd3-EBO-Z, one as a 
bivalent vaccine (1:1 mix with replication-defective chimpanzee 
adenovirus 3 vector expressing Sudan Ebola virus glycoprotein; 
US participants) and the other as a monovalent vaccine (UK 
participants). Both publications represent groups working 
within the WHO consortium. One publication described 
preclinical challenge trials in NHPs assessing the short-term 
(5 weeks after vaccination) and extended (10 months after 
vaccination) eﬃ  cacy of the vaccine.
Added value of this study
This study constitutes the ﬁ rst phase 1 report of monovalent 
ChAd3-EBO-Z vaccine in west Africans and compares four doses, 
consisting of 1 × 10¹⁰ particle units (pu), 2·5 × 10¹⁰ pu, 5 × 10¹⁰ pu, 
and 1 × 10¹¹ pu. The results in both Malian and US participants 
document that the 1 × 10¹¹ pu dose is well tolerated and 
signiﬁ cantly more immunogenic than are low doses in 
elicitation of antiglycoprotein antibodies measured with ELISA. 
91% of Malian and 60% of US participants given a single dose of 
ChAd3-EBO-Z attained titres that are associated with protection 
of NHPs against lethal challenge with wild-type Zaire Ebola 
virus, suggesting, by extrapolation, that this dose could protect 
humans against natural infection. A single booster dose of 
modiﬁ ed vaccinia Ankara expressing Zaire Ebola virus 
glycoprotein stimulated anamnestic antiglycoprotein antibody 
and CD4 and CD8 T-cell responses to glycoprotein peptides, 
suggesting, by extrapolation from results in NHPs, that this 
booster might extend the duration of high-level protection.
Implications of all the available evidence
With optimistic extrapolation of these results, a single 
1 × 10¹¹ pu dose of ChAd3-EBO-Z might be suﬃ  ciently well 
tolerated and immunogenic to be eﬀ ective in interruption of 
transmission of Ebola virus to family members and other close 
contacts of index patients if used in a ring vaccination tactic 
after rapid identiﬁ cation of cases. A heterologous prime and 
boost regimen consisting of a ChAd3-EBO-Z prime followed 
2–3 months afterwards by a boost with modiﬁ ed vaccinia 
Ankara expressing Zaire Ebola virus glycoprotein could confer 
long-term protection to subgroups (eg, health-care and front-
line workers) that need extended protection. 
See Online for appendix
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Recognising that administration to NHPs of a booster 
vaccination with a heterologous viral vector, MVA-
expressing Zaire Ebola virus glyco protein, enhances both 
humoral and cell-mediated immune responses and 
extends protection against challenge, we sought to obtain 
doses of MVA-expressing Zaire Ebola virus glycoprotein 
to do a nested booster study of the Malian volunteers 
primed with ChAd3-EBO-Z. Bavarian Nordic 
(Martinsried, Germany) provided 30 scarce doses of 
MVA-BN-Filo (which expresses Zaire Ebola virus and 
Sudan Ebola virus glycoproteins and other ﬁ lovirus 
proteins). To distribute this small number of doses and 
maximise the infor mation obtained, we designed a 
nested, randomised, double-blind, placebo-controlled 
booster trial to assess the eﬀ ect of MVA-BN-Filo versus 
saline placebo on the immune response. 
Participants provided written informed consent. The 
Malian study was approved by the University of Bamako 
Faculty of Medicine, Pharmacy and Odontostomatology 
Ethics Committee, Malian National Ethics Committee, 
and WHO Ethics Review Committee. The University of 
Maryland, Baltimore Institutional Review Board 
approved the Malian and US trials. 
Randomisation and masking
In the US trial, we randomly allocated (1:1) participants to 
receive 1 × 10¹⁰ viral particle units (pu) or 1 × 10¹¹ pu. The 
Malian trial was initially designed to test only two doses, 
2·5 × 10¹⁰ pu (group 1) and 5 × 10¹⁰ pu (group 2). Because 
this trial was, to our knowledge, the ﬁ rst time that 
ChAd3-EBO-Z was given to Africans, and only a few 
people had received the monovalent vaccine weeks earlier 
(during the week of Sept 17, 2014) at a trial done at the 
Centre for Clinical Vaccinology and Tropical Medicine at 
the University of Oxford10 (Oxford, UK), and 20 had 
received bivalent chimpanzee adenovirus 3-vectored 
Ebola vaccine at the National Institutes of Health 
(Bethesda, MD, USA; during Sept 2–23, 2014),11 we 
vaccinated the ﬁ rst ﬁ ve Malians in staggered progression 
after the ﬁ rst ﬁ ve Oxford vaccinees.10 Dose escalation to 
5 × 10¹⁰ pu occurred after the data safety monitoring board 
(DSMB) reviewed 7 day safety data from the recipients of 
2·5 × 10¹⁰ pu. When extra doses became available, after 
protocol approval, we randomly allocated additional 
Malians (1:1) to receive 2·5 × 10¹⁰ pu (group 3B) or 
5 × 10¹⁰ pu (group 3C) in double-blind fashion; open-label 
groups received 1 × 10¹⁰ pu (group 3A) or 1 × 10¹¹ pu 
(group 4). In the nested Malian study, we randomly 
allocated (1:1) Malians primed with ChAd3-EBO-Z to 
receive MVA-BN-Filo or placebo.
ARB generated randomisation sequences for 
randomised segments of the Malian trial and for the US 
trial. In the US trial, randomisation was accomplished 
through an online database and randomisation software 
(AdvantageEDC) managed by the EMMES Corporation 
(Rockville, MD, USA). We used blocked randomisation 
for both the Malian (block size of six) and US (block size 
of four) trials, and simple randomisation for the nested 
Malian study. Clinical staﬀ  assigned each enrolled 
participant a randomisation number from the electronic 
data entry system that corresponded to a treatment on a 
computer-generated randomisation list available only to 
the unmasked study pharmacist (MK) and vaccine 
administrator.
In the double-blind segments of the Malian trial, study 
investigators, clinical staﬀ , participants, and immunology 
laboratory staﬀ  were masked. The study pharmacist (MK) 
and vaccine administrator, who were not involved in 
other trial assessments, and the study statistician (ARB) 
were unmasked. In the open-label segments, invest-
igators were aware of dose assignment. In the US trial, 
study investigators were not masked to study allocation, 
but participants were masked to the dose of vaccine that 
they received.
Procedures
ChAd3-EBO-Z drug substance was manufactured at 
Advent (Pomezia, Italy), an Okairos (now GlaxoSmithKline) 
subsidiary, and drug product was vialled at the Vaccine 
Research Center Vaccine Pilot Plant (Frederick, MD, USA) 
under contract with the Vaccine Clinical Materials 
Program, Leidos Biomedical Research (Frederick, MD, 
USA). The vaccine is a sterile, aqueous, buﬀ ered solution 
that contains ChAd3-EBO-Z in single-dose vials. We stored 
vaccine at below –60°C. We derived the doses for Malian 
participants by adjustment of the volume of vaccine 
injected, as was done in the Oxford trial,10 to 110 μL 
(1 × 10¹⁰ pu), 275 μL (2·5 × 10¹⁰ pu), 550 μL (5 × 10¹⁰ pu), or 
1100 μL (1 × 10¹¹ pu). For US participants, we delivered the 
two doses (1 × 10¹⁰ pu or 1 × 10¹¹ pu) in 1·0 mL volume. We 
gave single doses of vaccine intramuscularly. We injected 
vaccines into the non-dominant arm triceps.
MVA-BN-Filo vaccine, which encodes Zaire Ebola virus 
and Sudan Ebola virus glycoproteins, Marburg virus 
glycoprotein, and Tai-Forest Ebola virus nucleoprotein, 
was manufactured by Impfstoﬀ werk Dessau-Torman 
(Dessau-Roßlau, Germany), and supplied as a liquid 
formulation in tris and NaCl in 2 mL vials; each 0·5 mL 
dose contained 3 × 10⁸ plaque-forming units. MVA-BN-Filo 
was the only MVA-expressing Zaire Ebola virus 
glycoprotein that was available to boost the Malian 
participants in a timely manner and, to our knowledge, 
represents the ﬁ rst use of MVA-BN-Filo in an African 
population.
We watched participants for immediate-onset adverse 
(eg, anaphylactic) reactions for 60 min after vaccination. 
Follow-up visits were on days 7, 14, 28, 90, and 180 after 
primary or booster vaccination. We also saw Malians 
on day 1; we contacted US participants by telephone 
on day 1. We recorded local reactions daily for 7 days after 
the vaccination and reported unsolicited symptoms for 
28 days after vaccination. We reviewed symptoms at each 
follow-up visit and collected blood for tests to monitor 
participants’ health status, including a full blood count, 
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urea and electrolyte measurements, and liver proﬁ le. We 
did severity grading of adverse events (AEs) and 
assignment of causal relation of unsolicited AEs 
according to predeﬁ ned criteria in the study protocols.
We measured plasma IgG responses to glycoproteins 
of Zaire Ebola virus (all participants) and Sudan Ebola 
virus (Malian 1 × 10¹¹ pu recipients only) with ELISA.12 
We expressed chimpanzee adenovirus 3-neutralising and 
adenovirus 5-neutralising antibodies as inhibitory con-
centration 90 reciprocal titres.13 We quantiﬁ ed Zaire 
Ebola virus glycoprotein-speciﬁ c T-cell responses with 
intracellular cytokine staining.11,14 We stimulated cryo-
preserved peripheral blood mononuclear cells obtained 
at 0 weeks, 2 weeks, and 4 weeks after ChAd3-EBO-Z 
vaccination and 0 weeks, 1 week, 2 weeks, and 4 weeks 
after MVA-BN-Filo boost with overlapping peptide pools 
for Zaire Ebola virus glycoprotein (Z1 and Z2). We then 
quantiﬁ ed memory CD4 and CD8 T cells  (deﬁ ned by 
CD45RA and CCR7 expression patterns) producing 
interleukin 2, interferon γ, or tumour necrosis factor α 
(TNFα).11,14 We deemed responders participants with CD4 
or CD8 responses to any peptide pool (measured by 
interleukin 2, interferon γ, or TNFα) after vaccination, as 
described elsewhere.14
Outcomes
The primary outcome was safety, measured with actively 
(solicited—ie, sought by investigators) collected data for 
AEs for 7 days after vaccination. The secondary outcome 
was immunogenicity, assessed with ELISA for antibody 
responses and an intracellular cytokine staining assay for 
T-cell responses. We measured baseline antivector 
antibodies using neutralisation assays. A full list of 
primary and secondary outcomes is given in the 
appendix.
Statistical analysis
The sample size of 91 for the Malian trial balances the 
need to avoid exposure of a large group to an unknown 
risk with the need for data from an adequate sample. We 
based group sample sizes on availability of study product. 
This sample size should allow establishment of the 
magnitude of AEs, rather than obtaining of signiﬁ cance 
for diﬀ erences between groups. A scarcity of vaccine 
doses and the desire to study the safety and immuno-
genicity of a range of dose levels drove sample sizes in 
the nested trial. In the US trial, the study design was 
phase 1 dose escalation based on a target accrual of 
20 adult participants divided equally between two dose 
groups. 
We reported ELISA antibody responses to Zaire Ebola 
virus glycoprotein as geometric mean titre (GMT), with 
95% CIs. We deﬁ ned positive responses as signiﬁ cant 
(α=0·05) increases in log-ELISA from baseline, with use 
of paired t tests.11 We used Fisher’s exact tests for 
between-group comparisons of proportions of subjects 
with positive responses or for responses of more than 
reference values, Student’s t tests for the magnitude of 
the antibody response after log transformation, and 
Wilcoxon tests to compare the magnitude of T-cell 
responses or non-normally distributed antibody titres. 
Tests were two-sided, without multiple comparisons 
adjustment. We used McNemar’s tests to assess whether 
CD4-positive and CD8-positive T-cell responses occurred 
in the same or diﬀ erent participants. We analysed 
associations between antibody and T-cell responses with 
Spearman’s correlation. We ﬁ tted a linear regression 
model to assess associations of prime-boost interval and 
priming ChAd3-EBO-Z dose with postboost ELISA 
response. We analysed and displayed T-cell intracellular 
cytokine staining data with SPICE 5.3.5.15 We used SAS 
9.3 for other analyses. Analyses were per protocol, but no 
participants were randomly allocated but not vaccinated 
and no participants received a product diﬀ erent from 
their randomisation assignment.
Clinical trial monitoring was provided by CVD–Mali 
and CVD monitors. A DSMB furnished independent 
oversight for the Malian trial, whereas a protocol review 
safety team oversaw the US trial. Both trials are registered 
with ClinicalTrials.gov, numbers NCT02231866 (US) and 
NCT02267109 (Malian).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
Between Oct 8, 2014, and Oct 23, 2014, 20 (22%) 
participants (group 1) in Mali received 2·5 × 10¹⁰ pu of 
ChAd3-EBO-Z, and between Nov 4, 2014, and Nov 6, 2014, 
we vaccinated a further 20 (22%) participants (group 2) 
with 5 × 10¹⁰ pu (ﬁ gure 1). Shortly after enrolment of 
groups 1 and 2 began, 40 additional doses of ChAd3-EBO-Z 
vaccine became available for use in Mali. Accordingly, 
after ethical committee approvals and DSMB con-
currence, on Nov 10, 2014, we vaccinated ten (11%) 
additional participants (group 3A) with a dose of 
1 × 10¹⁰ pu, thereby providing a low-dose group for 
comparison. Between Nov 13, 2014, and Nov 15, 2014, we 
randomly allocated 30 (33%) additional participants 
(15 [16%] to each group) to receive a dose of either 
2·5 × 10¹⁰ pu (group 3B) or 5 × 10¹⁰ pu (group 3C), with 
double-blind clinical follow-up. Finally, 11 additional 
doses became available for the Mali trial; with ethical 
approval of the amended protocol and DSMB 
Figure 1: Trial proﬁ le
(A) Malian trial. (B) US trial. ChAd3-EBO-Z=replication-defective chimpanzee 
adenovirus 3 vector vaccine expressing Zaire Ebola virus glycoprotein. 
MVA-BN-Filo=modiﬁ ed vaccinia Ankara expressing Zaire Ebola virus glycoprotein 
and other ﬁ lovirus antigens. pu=particle units.
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119 assessed for eligibility
1 loss to follow-up 
 after day 7
29 ineligible for nested 
 trial because dose 
 received still masked
First 5 participants ineligible for 
nested trial because of extended 
time since vaccination
2 refused
91 allocated
Group 1
20 given dose of 2·5 × 1010 pu 
 of ChAd3-EBO-Z
 (open label)
Group 2
20 given dose of 5 × 1010 pu 
 of ChAd3-EBO-Z
 (open label)
Group 3A
10 given dose of 1 × 1010 pu 
 of ChAd3-EBO-Z
 (open label)
Group 4
11 given dose of 1 × 1011 pu  
 of ChAd3-EBO-Z
 (open label)
Group 3B
15 given dose of 2·5 × 1010 pu  of 
 ChAd3-EBO-Z
Group 3C
15 given dose of 5 × 1010 pu of 
 ChAd3-EBO-Z 
 (double blind, randomised 1:1)
20 included in 28 day
 analysis and completed 
 follow-up per protocol
20 included in 28 day
 analysis and completed 
 follow-up per protocol
10 included in 28 day
 analysis and completed 
 follow-up per protocol
11 included in 28 day
 analysis and completed 
 follow-up per protocol
14  who received 2·5 × 1010 pu and 
 15 who received 5 × 1010 pu 
 included in 28 day analysis and 
 completed follow-up per protocol 
28 not enrolled
 25 ineligible
 3 because accrual goals already met
15 eligible for nested trial
7 assigned 
 MVA-BN-Filo 
 and completed 
 follow-up 
 per protocol
 (double blind, 
 randomised 1:1)
6 assigned
 placebo and 
 completed 
 follow-up per 
 protocol
 (double blind,
 randomised 1:1)
10 assigned 
 MVA-BN-Filo 
 and completed 
 follow-up 
 per protocol
 (double blind,
 randomised 1:1)
9 assigned
 placebo and 
 completed 
 follow-up per 
 protocol
 (double blind,
 randomised 1:1)
5 assigned 
 MVA-BN-Filo 
 and completed 
 follow-up 
 per protocol
 (double blind,
 randomised 1:1)
5 assigned
 placebo and 
 completed 
 follow-up per 
 protocol
 (double blind, 
 randomised 1:1)
5 assigned 
 MVA-BN-Filo 
 and completed 
 follow-up 
 per protocol
 (double blind,
 randomised 1:1)
5 assigned
 placebo and 
 completed 
 follow-up per 
 protocol
 (double blind,
 randomised 1:1)
20 eligible for nested trial 10 eligible for nested trial 11 eligible for nested trial 0 eligible for nested trial
13 screened 20 screened
20 randomised
10 screened 11 screened
1 did not pass cardiac screening 1 refused vaccination after screening
Group 1
10 given dose of 1 × 1010 pu of ChAd3-EBO-Z (single blind) 
10 included in 28 day analysis and completed follow-up per protocol
28 assessed for eligibility
8 not enrolled
 5 ineligible
 1 withdrew consent
 2 not enrolled because accrual goals already met
Group 2
10 given dose of 1 × 1011 pu of ChAd3-EBO-Z (single blind) 
10 included in 28 day analysis and completed follow-up per protocol
A
B
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con currence, between Nov 25, 2014, and Nov 26, 2014, 11 
(12%) participants received (open label) a 1 × 10¹¹ pu dose. 
Between Nov 10, 2014, and Nov 18, 2014, we vaccinated 
20 US participants with ChAd3-EBO-Z (ten [50%] with 
1 × 10¹⁰ pu and ten [50%] with 1 × 10¹¹ pu).
Because of the small number of doses of MVA-BN-Filo 
available, 56 (62%) of the 91 Malians primed with 
ChAd3-EBO-Z were deemed eligible for the nested trial, 
in which we randomly allocated them to receive 
MVA-BN-Filo or placebo. Eligible participants came from 
groups 1, 2, 3A, and 4: 15 (27%) of 20 participants from 
group 1 (we excluded the ﬁ rst ﬁ ve vaccinees because they 
had received their vaccine several weeks earlier than the 
remaining 15 had because the safety data from these ﬁ rst 
ﬁ ve participants were reviewed before further 
vaccinations took place); the 20 (36%) participants from 
group 2; the ten (18%) participants from group 3A; and 
the 11 (20%) participants from group 4. The 29 (one was 
lost to follow-up after day 7) additional vaccinees who had 
been randomly allocated to receive 2·5 × 10¹⁰ pu 
(group 3B) or 5 × 10¹⁰ pu (group 3C) were ineligible 
because the dose that they had received was still masked. 
We had insuﬃ  cient time to reprogram electronic data 
capture to accommodate random allo cation of a 
secondary subgroup while preserving masking of the 
priming dose. Between Feb 9, 2015, and Feb 16, 2015, we 
enrolled 52 (93%) of these 56 eligible participants (three 
declined to participate and one was medically ineligible 
based on cardiac screening criteria), representing all four 
ChAd3-EBO-Z doses and a fairly tight range of intervals 
(79–111 days) since priming immunisation with 
ChAd3-EBO-Z, who we randomly allocated to receive 
MVA-BN-Filo (27 [52%] participants) or saline placebo 
(25 [48%] participants), followed up clinically in double-
blind fashion.
Analysis of viral titre in vials from the vaccine lot used 
in the clinical trials showed 1·0 × 10¹¹ pu/mL when 
tested at the National Institutes of Health (Bethesda, 
MD, USA) and 9·1 × 10¹⁰ pu/mL when tested at the 
Jenner Institute, University of Oxford (Oxford, UK). 
Table 1 summarises participants’ demographic and other 
characteristics; all Malians were health-care and front-
line workers.
Table 2 summarises the frequency and severity of 
solicited AEs (unsolicited—ie, oﬀ ered voluntarily by 
participants—AEs described in appendix), by dose, for 
7 days after ChAd3-EBO-Z vaccination or MVA-BN-Filo 
booster (primary outcome). Most AEs were mild, with 
no unexpected serious adverse reactions suspected. One 
(1%) serious AE in Mali (tuberculous peritonitis; received 
2·5 × 10¹⁰ pu) was unrelated to vaccine. The predominant 
solicited AE was fever, occurring in seven (8%) of 
91 Malian (ﬁ ve [5%] received 5 × 10¹⁰ pu and two [2%] 
received 1 × 10¹¹ pu) and four [20%] of 20 US (all received 
1 × 10¹¹ pu) participants; ten of 11 fevers resolved by 24 h 
after vaccination and none persisted for longer than 
24 h. One (1%) fever of 37·6°C occurred in a Malian 
volunteer on day 2 after vaccination (5 × 10¹⁰ pu), but still 
resolved within 24 h. One (1%) Malian (5 × 10¹⁰ pu) and 
two (10%) US (1 × 10¹¹ pu) vaccinees had fevers with 
temperatures higher than 38·5°C, accompanied by 
systemic symptoms (eg, fatigue, myalgia, arthralgia, 
headache, chills, or nausea). The appendix summarises 
laboratory abnormalities noted up to day 28. Most 
episodes (ten of 11) of the most frequent abnormality, 
lymphopenia, occurred on day 1 after vaccination and 
self-resolved. In the Malian participants, we noted single 
cases of moderate (109 × 10⁹/L; 5 × 10¹⁰ pu) and severe 
(63 × 10⁹/L; 2·5 × 10¹⁰) asymptomatic thrombocytopenia 
on day 1 after vaccination that resolved by day 7.
Malian adults US adults
Phase 1b trial Nested booster study Phase 1 trial
1 × 10¹⁰ pu of 
ChAd3-EBO-Z 
(n=10)
2·5 × 10¹⁰ pu of 
ChAd3-EBO-Z 
(n=35)
5 × 10¹⁰ pu of 
ChAd3-EBO-Z 
(n=35)
1 × 10¹¹ pu of 
ChAd3-EBO-Z 
(n=11)
Overall 
(n=91)
Boosted with 
MVA-BN-Filo 
(n=27)
Boosted with 
saline placebo 
(n=25)
Overall 
(n=52) 
1 × 10¹⁰ pu of 
ChAd3-EBO-Z 
(n=10)
1 × 10¹¹ pu 
(n=10)
Overall (n=20)
Sex
Male 10 (100%) 29 (83%) 30 (86%) 4 (36%) 73 (80%) 19 (70%) 20 (80%) 39 (75%) 4 (40%) 5 (50%) 9 (45%)
Female 0 6 (17%) 5 (14%) 7 (64%) 18 (20%) 8 (30%) 5 (20%) 13 (25%) 6 (60%) 5 (50%) 11 (55%)
Age (years) 33·7 (6·8) 35·9 (6·0) 33·7 (6·9) 31·0 (7·1) 34·2 (6·8) 33·6 (5·4) 34·6 (8·3) 34·1 (6·9) 32·9 (12·2) 37·6 (10·4) 35·3 (11·3)
Race
Asian 0 0 0 0 0 0 0 0 2 (20%) 2 (10%)
Black 10 (100%) 35 (100%) 35 (100%) 11 (100%) 91 (100%) 27 (100%) 25 (100%) 52 (100%) 2 (20%) 2 (20%) 4 (20%)
White 0 0 0 0 0 0 0 0 8 (80%) 6 (60%) 14 (70%)
Hispanic or Latino 0 0 0 0 0 0 0 0 1 0 1 (5%)
Body-mass index 
(kg/m²)
23·5 (3·4) 26·4 (4·3) 24·6 (4·2) 29·6 (7·4) 25·6 (4·9) 25·6 (6·0) 25·6 (4·4) 25·6 (5·2) 28·6 (5·0) 24·6 (3·4) 26·6 (4·6)
Data are n (%) or mean (SD). pu=particle units. ChAd3-EBO-Z=replication-defective chimpanzee adenovirus 3 vector vaccine expressing Zaire Ebola virus glycoprotein. MVA-BN-Filo=modiﬁ ed vaccinia Ankara 
expressing Zaire Ebola virus glycoprotein and other ﬁ lovirus antigens.
Table 1: Baseline characteristics
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AEs were uncommon in the 27 participants boosted 
with MVA-BN-Filo. By day 7, the most common local 
reactions were injection-site pain or tenderness (table 2). 
Two (7%) participants boosted with MVA-BN-Filo 
developed mild fever and associated injection-site pain, 
mild myalgia, headache, and fatigue. Thick smears for 
malaria parasites were negative, and both were well 
by day 3. Other AEs noted up to day 28 are summarised 
in the appendix. Of 25 participants allocated to placebo 
booster, one (4%) had an isolated mild fever of 37·9°C. 
We measured plasma IgG responses to Zaire Ebola 
virus glycoprotein with ELISA and compared them with 
titres that conferred protection in NHP eﬃ  cacy trials 
(secondary outcome).5 Table 3 and the appendix display 
the proportion of ChAd3-EBO-Z vaccinees in each group 
who showed serological responses by day 28, and the 
GMT. We noted high serological response rates for all 
dose groups, but GMT was signiﬁ cantly higher in 
recipients of 1 × 10¹¹ pu than in those given low doses 
(1 × 10¹⁰ pu, 2·5 × 10¹⁰ pu, and 5 × 10¹⁰ pu). The proportion 
of Malian vaccinees with day 28 reciprocal titres of 500 or 
higher, 1000 or higher, or 1500 or higher was signiﬁ cantly 
higher in recipients of the high dose than in those given 
low vaccine doses (table 3, ﬁ gure 2). After vaccination 
with ChAd3-EBO-Z, the GMT peaked at 28 days and fell 
only slowly through the next 12 weeks. After boosting 
with MVA-BN-Filo, the GMT rapidly rose by 36 times 
and persisted at this high level. The antiglycoprotein 
Malian adults US adults
Phase 1b trial Nested booster study Phase 1 trial
1 × 10¹⁰ pu of 
ChAd3-EBO-Z 
(n=10)
2·5 × 10¹⁰ pu of 
ChAd3-EBO-Z 
(n=35)
5 × 10¹⁰ pu of 
ChAd3-EBO-Z 
(n=35)
1 × 10¹¹ pu of 
ChAd3-EBO-Z 
(n=11)
Overall 
(n=91)
Boosted with 
MVA-BN Filo 
(n=27)
Boosted with 
saline placebo 
(n=25)
Overall 
(n=52) 
1 × 10¹⁰ pu of 
ChAd3-EBO-Z 
(n=10)
1 × 10¹¹ pu of 
ChAd3-EBO-Z 
(n=10)
Overall 
(n=20)
Local*
Pain and tenderness
Mild 3 (30%) 13 (37%) 14 (40%) 8 (73%) 38 (42%) 13 (48%) 0 13 (25%) 4 (40%) 4 (40%) 8 (40%)
Moderate 0 0 0 1 (9%) 1 (1%) 2 (7%) 0 2 (4%) 0 0 0
Systemic
Fever (oral temperature)
37·6–38·5°C 0 0 4 (11%) 2 (18%) 6 (7%) 2 (7%) 1 (4%) 3 (6%) 0 2 (20%) 2 (10%)
38·6–39·5°C 0 0 1 (3%) 0 1 (1%) 0 0 0 0 2 (20%) 2 (10%)
Fatigue
Mild 2 (20%) 10 (29%) 10 (29%) 3 (27%) 25 (27%) 12 (44%) 0 12 (23%) 3 (30%) 5 (50%) 8 (40%)
Moderate 0 1 (3%) 2 (6%) 0 3 (3%) 0 0 0 0 2 (20%) 2 (10%)
Myalgia
Mild 0 4 (11%) 3 (9%) 1 (9%) 8 (9%) 7 (26%) 0 7 (13%) 1 (10%) 2 (20%) 3 (15%)
Moderate 0 0 2 (6%) 0 2 (2%) 0 0 0 0 3 (30%) 3 (15%)
Arthralgia
Mild 0 2 (6%) 1 (3%) 2 (18%) 5 (5%) 3 (11%) 0 3 (6%) † † †
Moderate 0 0 2 (6%) 0 2 (2%) 0 0 0 † † †
Headache
Mild 5 (50%) 14 (40%) 6 (17%) 4 (36%) 29 (32%) 13 (48%) 3 (12%) 16 (31%) 4 (40%) 5 (50%) 9 (45%)
Moderate 0 1 (3%) 2 (6%) 0 3 (3%) 1 (4%) 0 1 (2%) 1 (10%) 2 (20%) 3 (15%)
Chills
Mild 0 1 (3%) 4 (11%) 1 (9%) 6 (7%) 1 (4%) 0 1 (2%) 0 1 (10%) 1 (5%)
Moderate 0 0 1 (3%) 0 1 (1%) 1 (4%) 0 1 (2%) 0 2 (20%) 2 (10%)
Nausea
Mild 0 1 (3%) 1 (3%) 1 (9%) 3 (3%) 1 (4%) 0 1 (2%) 0 0 0
Moderate 0 0 0 0 0 0 0 0 0 1 (10%) 1 (5%)
Haematological
Lymphopenia
750–1000 cells per μL 0 4 (11%) 3(9%) 3 (27%) 10 (11%) 2 (7%) 0 2 (4%) 3 (30%) 0 3 (15%)
500–749 cells per μL 0 0 1 (3%) 1 (9%) 2 (2%) 1 (4%) 0 1 (2%) 0 0 0
Data are n (%). The maximum solicited local and systemic reactogenicity symptoms are depicted through to day 7 after vaccination. pu=particle units. ChAd3-EBO-Z=replication-defective chimpanzee adenovirus 
3 vector vaccine expressing Zaire Ebola virus glycoprotein. MVA-BN-Filo=modiﬁ ed vaccinia Ankara expressing Zaire Ebola virus glycoprotein and other ﬁ lovirus antigens. *Local adverse events were pain, 
erythema, induration and swelling, pruritus, and warmth. We noted one episode of mild induration and swelling in a Malian participant (1 × 10¹¹ pu). We recorded no erythema events. †Signs or symptoms that 
were not collected. 
Table 2: Adverse events
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Malian adults US adults
1 × 10¹⁰ pu (n=10) 2·5 × 10¹⁰ pu (n=34)* 5 × 10¹⁰ pu (n=35) 1 × 10¹¹ pu (n=11) 1 × 10¹⁰ pu (n=10) 1 × 10¹¹ pu (n=10)
Positive response by day 28 10
(100·0% [69·2–100·0])
33
(97·1% [84·7–99·9])
29
(82·9% [66·4–93·4])
11
(100% [71·5–100·0])
10
(100% [69·2–100·0])
10
(100% [69·2–100·0])
Day 28 geometric titre 295·0
(114·8–758·2)
220·4
(155·9–311·6)
466·0
(289·1–750·9)
1446·9
(759·4–2756·8)
531·5
(249·4–1132·5)
1255·9
(379·7–4154·2)
Day 28 reciprocal titres
≥500 3
(30·0% [6·7–65·2])
5
(14·7% [5·0–31·1])
15
(42·9% [26·3–60·6])
10
(90·9% [58·7–99·8])
5
(50·0% [18·7–81·3])
7
(70·0% [34·8–93·3])
≥1000 1
(10·0% [0·3–44·5])
3
(8·8% [1·9–23·7])
7
(20·0% [8·4–36·9])
10
(90·9% [58·7–99·8])
3
(30·0% [6·7–65·2])
6
(60·0% [26·2–87·8])
≥1500 1
(10·0% [0·3–44·5])
2
(5·9% [0·7–19·7])
6
(17·1% [6·6–33·6])
6
(54·5% [23·4–83·3])
3
(30·0% [6·7–65·2])
6
(60·0% [26·2–87·8])
Baseline reciprocal titre ≥200
Chimpanzee adenovirus 3-neutralising 
antibody
2
(20·0% [2·5–55·6])
4
(11·8% [3·3–27·5])
3
(8·6% [1·8–23·1])
0
(0% [0–28·5])
·· ··
Adenovirus 5-neutralising antibody 6
(60·0% [26·2–87·8])
30
(88·2% [72·6–96·7])
30
(85·7% [69·7–95·2])
8
(72·7% [39·0–94·0])
·· ··
Data are n (% [95% CI]) or mean (95% CI). This table with comparisons with other studies is provided in the appendix. pu=particle units. *One loss to follow-up after day 7.  
Table 3: Serological responses after replication-defective chimpanzee adenovirus 3 vector vaccine expressing Zaire Ebola virus glycoprotein vaccination
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1
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A ChAd3-EBO-Z and placebo boost (n=25)
ChAd3-EBO-Z and MVA-BN-Filo (n=27)
Time since ChAd3-EBO-Z prime (weeks)
B High dose of ChAd3-EBO-Z (1 × 1011 pu) and placebo boost (n=5)
Low doses of ChAd3-EBO-Z (1 × 1010 pu, 2·5 × 1010 pu, and 5× 1010 pu) 
and placebo boost (n=20)
GMT
Individual titres
BoostPrime Boost
Boost Boost
Prime
Prime Prime
Figure 2: Anti-Zaire Ebola virus glycoprotein ELISA titres (background subtracted) for the Malian participants in the nested MVA-BN-Filo booster trial
Titres of individual participants are plotted as open circles at the actual week after priming immunisation with ChAd3-EBO-Z vaccine. GMTs are plotted as ﬁ lled circles 
with associ ated 95% CIs. For participants in the booster study, their boost visits ranged from 11·2 weeks to 15·8 weeks after priming; the GMT for the boost visit is 
plotted at the median of 13 weeks, and the GMTs for postboost visits are plotted at the subsequent target intervals (ie, 1 week, 2 weeks, and 4 weeks after boosting). 
(A) Participants primed with ChAd3-EBO-Z and then boosted with saline placebo are compared with those primed with ChAd3-EBO-Z and then boosted with 
MVA-BN-Filo. (B) The longevity of the antiglycoprotein response in participants vaccinated with the 1 × 10¹¹ pu high dose of ChAd3-EBO-Z and boosted with saline 
placebo is shown and compared with the magnitude of response of the participants who received low doses (1 × 10¹⁰ pu, 2·5 × 10¹⁰ pu, or 5 × 10¹⁰ pu) of ChAd3-EBO-Z, 
followed by a saline booster. ChAd3-EBO-Z=replication-defective chimpanzee adenovirus 3 vector vaccine expressing Zaire Ebola virus glycoprotein. GMT=geometric 
mean titre. MVA-BN-Filo=modiﬁ ed vaccinia Ankara expressing Zaire Ebola virus glycoprotein and other ﬁ lovirus antigens. pu=particle units.
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antibody persisted at a much higher level in recipients of 
the high dose of ChAd3-EBO-Z than in those of the low 
doses (appendix).
The participants in the booster study did not diﬀ er 
from the non-boosted participants in terms of baseline 
characteristics (table 1), and the MVA-BN-Filo booster 
recipients were not diﬀ erent from the saline controls 
with respect to age, ChAd3-EBO-Z priming dose, or 
prime-boost interval (MVA-BN Filo mean interval 
13·8 weeks [SD 0·29]; placebo 13·7 weeks [0·29]). 
Serological responses of the Malian MVA-BN-Filo 
booster participants are summarised in table 4, ﬁ gure 2, 
and the appendix). The GMT 28 days after boosting 
(9279·6 [95% CI 7193·2–11 971·2]) was signiﬁ cantly 
higher than that 28 days after priming (356·4 
[207·3–612·6]) for the 27 participants boosted with 
MVA-BN-Filo (geometric mean-fold increase of 26·0 
[14·6–46·3]; p<0·0001); the rise to 28 days after boosting 
compared with preboost GMT (276·0 [183·0–416·4]) 
was similarly signiﬁ cant (geometric mean-fold increase 
of 33·6 [22·8–49·6]; p<0·0001). The ﬁ ve Malian 
participants who received 1 × 10¹¹ pu of ChAd3-EBO-Z 
and were subsequently boosted with MVA-BN-Filo 
oﬀ ered an opportunity to assess whether ChAd3-EBO-Z 
had primed these individuals to mount accelerated 
serological responses to heterologous Sudan Ebola 
virus glycoprotein following the boost. 1 week after the 
boost, four (80%) of these ﬁ ve participants exhibited 
serological responses to the Sudan Ebola virus 
glycoprotein (appendix). By contrast, only one (20%) of 
these ﬁ ve showed a minimum serological response to 
the distantly related (diﬀ erent genus) Marburg virus 
glycoprotein after the boost (data not shown).
The durability of the antibody response to Zaire Ebola 
virus glycoprotein after administration of high-dose 
(1 × 10¹¹ pu) ChAd3-EBO-Z alone was assessed in the ﬁ ve 
recipients of this dose who subsequently received saline 
booster and provided plasma specimens 180 days after 
the boost—ie, 259 days after priming (secondary 
outcome, appendix). Even after 259 days, we noted only a 
very shallow slope of decay of antibody titres, showing 
impressive longevity of the antibody response after 
administration of a single high dose of ChAd3-EBO-Z.
The appendix shows the progressive ﬂ ow cytometry 
gating strategy used to enumerate antigen-speciﬁ c T cells. 
T-cell responses to primary immunisation with 
ChAd3-EBO-Z and after MVA-BN-Filo boosting are 
summarised in the appendix (secondary outcome). T-cell 
responses after priming were slight and of small 
magnitude: 15 (31%) of 49 participants showed either 
positive CD4 or CD8 responses after priming with 
ChAd3-EBO-Z, including eight (16%) who mounted 
measurable CD8 T-cell responses and 11 (22%) who 
showed CD4 T-cell responses. We noted a strong 
association between CD4 and CD8 responses in individual 
participants, except at 7 days after the MVA-BN-Filo boost, 
Malian adults after ChAd3-EBO-Z Malians adults after MVA-BN-Filo
1 × 10¹⁰ pu (n=10) 2·5 × 10¹⁰ pu (n=13) 5 × 10¹⁰ pu (n=19) 1 × 10¹¹ pu (n=10) Overall (n=52) 1 × 10⁸ PFU (n=27) Saline placebo (n=25)*
Positive response by
Day 7 2
(20·0% [2·5–55·6])
3
(23·1% [5·0–53·8])
2
(10·5% [1·3–33·1])
0
(0% [0–30·8])
7
(13·5% [5·6–25·8])
27
(100% [87·2–100·0])
21
(87·5% [67·6–97·3])
Day 28 10
(100% [69·2–100·0])
13
(100% [75·3–100·0])
18
(94·7% [74·0–99·9])
10
(100% [69·2–100·0])
51
(98·1% [89·7 to 100·0])
27
(100% [87·2–100·0])
20
(83·3% [62·6–95·3])
Geometric mean titre
Day 7 16·2
(8·2–32·2)
6·4
(3·0–13·6)
4·7
(1·7–13·2)
6·5
(1·9–21·7)
·· 11 209·3
(8552·6–14 691·4)
341·3
(182·2–637·1)
Day 28 295·0
(114·8–758·2)
204·6
(99·9–423·5)
555·8
(282·2–1094·6)
1493·6
(727·6–3065·9)
·· 9279·6
(7193·2–11 971·2)
261·3
(173·9–392·7)
Day 7 reciprocal titres
≥500 0
(0% [0–30·8])
0
(0% [0–24·7])
1
(5·3% [0·1–26·0])
0
(0% [0–30·8])
1
(1·9% [0·0–10·2])
27
(100% [87·2–100·0])
7
(29·2% [12·6–51·0])
≥1000 0
(0% [0–30·8])
0
(0% [0–24·7])
1
(5·3% [0·1–26·0])
0
(0% [0–30·8])
1
(1·9% [0·0–10·2])
27
(100% [87·2–100·0])
5
(20·1% [7·1–42·2])
Day 28 reciprocal titres
≥500 3
(30·0% [1·6–58·4])
2
(15·4% [1·9–45·4])
8
(42·1% [20·6–66·5])
9
(90·0% [55·5–99·7])
22
(42·3% [28·7–56·8])
27
(100% [87·2–100·0])
6
(25·0% [9·8–46·7])
≥1000 1
(10% [0·2–4·5])
2
(15·4% [1·9–45·4])
3
(15·8% [3·4–39·6])
9
(90·0% [55·5–99·7])
15
(28·8% [17·1–43·1])
27
(100% [87·2–100·0])
3
(12·5% [2·7–32·4])
≥1500 1
(10% [0·2–4·5])
1
(7·7% [0·2–36·0])
3
(15·8% [3·4–39·6])
6
(60·0% [26·2–87·8])
11
(21·2% [11·1–34·7])
27
(100% [87·2–100·0])
0
(0% [0–14·2])
Data are n (% [95% CI]) or mean (95% CI). This table with comparisons with other studies is provided in the appendix. ChAd3-EBO-Z=replication-defective chimpanzee adenovirus 3 vector vaccine expressing 
Zaire Ebola virus glycoprotein. MVA-BN-Filo=modiﬁ ed vaccinia Ankara expressing Zaire Ebola virus glycoprotein and other ﬁ lovirus antigens. pu=particle units. PFU=plaque-forming units. *One participant did 
not provide a blood specimen on day 7 and one did not provide one on day 28. 
Table 4: Serological responses after ChAd3-EBO-Z and MVA-BN-Filo or saline placebo vaccinations
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when a higher proportion of the 25 individuals had a CD8 
response than had a CD4 response (two [8%] CD4-negative 
and CD8-negative, seven [28%] CD4-negative and CD8-
positive, and 16 [64%] CD4-positive and CD8-positive; 
McNemar’s test p=0·0082). Cell-mediated immunity 
responses after priming with ChAd3-EBO-Z were stable 
and long-lived, as shown over time for the 25 participants 
primed with ChAd3-EBO-Z who later received a placebo 
booster. By contrast, of the 27 participants boosted with 
MVA-BN-Filo, we noted high-magnitude postboost CD4 
and CD8 responses in 23 (85%) participants (appendix). 
Similar to after priming, we noted a high degree of 
concordance between participants who showed both CD4 
and CD8 responses. Most Zaire Ebola virus glycoprotein-
speciﬁ c CD8 memory T cells were multifunctional, 
producing both interferon γ and TNFα, or all three 
cytokines (interferon γ, TNFα, and interleukin 2); 25% of 
CD8 T cells were interferon γ single-positive. 
Discussion
Our results identiﬁ ed the ChAd3-EBO-Z dose for large-
scale manufacture of the formulation slated for phase 2 
and 3 trials in Africa. A single 1 × 10¹¹ pu dose of 
ChAd3-EBO-Z elicited strong antiglycoprotein antibody 
responses in all participants. Glycoprotein-speciﬁ c anti-
bodies elicited by adenovirus 5 and chimpanzee 
adenovirus 3-vectored vaccines constitute a non-
mechanistic correlate of protection against otherwise 
lethal Ebola virus challenge to NHPs,5,9,16 although 
T cells seem key in mediation of protection conferred by 
adenovirus-vectored and DNA Ebola vaccines.5,17 Of 
NHPs immunised with adenovirus 5-vectored Ebola 
vaccine and challenged about 1 month later,5,9 animals 
that attained reciprocal titres of 1000 or higher (with use 
of ELISA as described by Sullivan and colleagues5) 
showed 77% vaccine eﬃ  cacy against death. Similarly, 
NHPs that were vaccinated with single-dose chimpanzee 
adenovirus 3-vectored Zaire Ebola virus vaccine and 
attained reciprocal titres of 967 or higher were 100% 
protected against lethal challenge at 5 weeks.9 Thus, the 
ﬁ nding that 90·9% of Malian recipients of 1 × 10¹¹ pu 
attained reciprocal titres of 1000 or higher is 
encouraging, generating optimism that this vaccine 
dose might confer high-level protection to vaccinated 
human beings in the ﬁ eld, at least in the short term. 
Many believe that the level of infective inocula to which 
humans are naturally exposed is much less than that of 
parenteral inocula given to NHPs. If so, ChAd3-EBO-Z 
could prove useful for diminishing of transmission in 
deﬁ ned target groups in future Ebola outbreaks. In 
NHPs, Zaire Ebola virus glycoprotein-speciﬁ c CD8 
memory T cells expressing both interferon γ and TNFα 
were associated with short-term protection (5 week 
challenge) after one dose of ChAd3-EBO-Z, whereas 
CD8 memory T cells positive for all three cytokines after 
booster with MVA-BN-Filo were associated with 
extended protection (10 month challenge).9
Subpopulations at high risk of transmission of Ebola 
virus in Africa consist of two distinct categories. The 
ﬁ rst consist of family members, neighbours, and other 
close contacts with people with conﬁ rmed Ebola cases. 
The second includes health-care and other front-line 
workers, and people who perform ritual funeral 
practices for patients who have died from Ebola. High-
coverage, concentric, single-dose containment ring 
vaccination with immunogenic Ebola vaccines for 
people in and around the households of people with 
index Ebola cases could diminish transmission between 
family members, neighbours, and known contacts, as 
was achieved with the surveillance and containment 
strategy that interrupted smallpox transmission in west 
Africa.18,19 For reactive vaccination to successfully contain 
Ebola virus disease outbreaks, a logistically practical, 
single-dose regimen that confers high-level eﬃ  cacy 
(even if in the short term) and enables high coverage is 
needed. The precedent for this strategy was established 
with the replicating recombinant vesicular stomatitis 
virus vector expressing Zaire Ebola virus glycoprotein 
(rVSV-ZEBOV) vaccine in a phase 3 ﬁ eld trial of eﬃ  cacy 
in Guinea.20 Within a few days of laboratory conﬁ rmation 
of an Ebola case, a cluster of all contacts and of their 
contacts was deﬁ ned, and the cluster was randomly 
allocated to either ring vaccination of consenting 
contacts around the case to begin immediately or only 
after a 21 day delay.20 The primary per-protocol analysis, 
which compared the incidence of laboratory-conﬁ rmed 
Ebola in eligible vaccinated contacts in immediate ring 
vaccination clusters with that in those in delayed ring 
vaccination clusters, was limited to conﬁ rmed cases that 
had an onset of illness 10 days or longer after 
randomisation. Contacts of conﬁ rmed cases were 
signiﬁ cantly protected if ring vaccination with rVSV-
ZEBOV was begun immediately rather than after a 
21 day delay.20 We expect that if ring vaccination was 
used with high-dose ChAd3-EBO-Z, the vaccine would 
be similarly eﬀ ective.
A comparison would be interesting of the ELISA 
antibody responses to Zaire Ebola virus glycoprotein 
shown by the Malians who received 1 × 10¹¹ pu of 
ChAd3-EBO-Z with those of Africans who received 
2 × 10⁷ plaque-forming units of rVSV-ZEBOV, as used in 
the Guinea ring vaccination ﬁ eld trial.20 So far, no data 
have been published for immune responses with this 
dose in Africans to allow a comparison. Data exist for 
serological responses of participants in Gabon and 
Kenya who received a dose of rVSV-ZEBOV one log 
lower than those in the Guinea ﬁ eld trial; however, the 
ELISA methods of measurement of antiglycoprotein 
were diﬀ erent to those used to obtain the data in the 
Malian trial described in this report.21 Publication of 
results of the phase 2 safety and immunogenicity com-
ponent of the Partnership for Research on Ebola 
Vaccines in Liberia trial (NCT02344407) might provide 
data for this point.
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Health-care, front-line, and funeral workers who have 
repetitive exposures to Ebola for extended periods need a 
vaccination regimen that confers more durable protection 
than what is expected to be derived from ChAd3-EBO-Z 
alone (at least on the basis of NHP studies).9 Fortunately, 
accessibility of these individuals makes delivery of a 
complex vaccination regimen (two spaced doses of two 
diﬀ erent vaccines) feasible. Accordingly, boosting of 
front-line workers with heterologous MVA vector 
expressing Ebola virus glycoprotein could extend the 
duration of high-level protection, as was noted in NHPs.9 
Antibody and T-cell responses of Malians boosted with 
MVA-BN-Filo show its powerful boosting capacity.
When these trials began, the scarcity of vaccine doses 
constrained trial design options. Some consortium 
partners proposed maximising the potential number of 
doses with testing of low doses containing 1 × 10¹⁰ pu, 
2·5 × 10¹⁰ pu, and 5 × 10¹⁰ pu.10 Results with a 
chimpanzee adenovirus 3-vectored hepatitis C vaccine 
with use of such doses provided a rationale.22 Other 
partners argued for testing of two widely separated 
doses (1 × 10¹⁰ and 1 × 10¹¹ pu) as a starting point to 
guide further studies.11 In this study, we tested all four 
doses of ChAd3-EBO-Z, once suﬃ  cient vaccine doses 
became available. This strategy acknowledged the 
possibility that west Africans, diﬀ ering in genetic 
background, nutritional state, socioeconomic level, and 
past exposure to adenoviruses and other pathogens, 
might mount immunological responses distinct from 
those of consortium participants from Europe and 
North America who were 80–90% white and living in 
aﬄ  uence. This strategy proved fortuitous because we 
documented immunological superiority of 1 × 10¹¹ pu to 
other doses. Importantly, adverse reactions were 
uncommon at this dose. No Malians and only two of 
ten US recipients of 1 × 10¹¹ pu had fever with a 
temperature of 38·6°C or higher, and none had one 
with a temperature of 39·6°C or higher. Short-lived 
fevers will not interfere with ring vaccination.
The results reported in this study paved the way for 
phase 2 trials in adults (PACTR201504001092179) and 
children (EudraCT 2014-004714-28) and for a phase 3 
eﬃ  cacy trial in Guinea with the 1 × 10¹¹ pu dose of 
ChAd3-EBO-Z to follow completion of testing of VSV-
ZEBOV in the Ebola ça Suﬃ  t trial.23 The partners that 
collectively managed the ﬁ eld trial operation in Guinea 
decided to proceed with a second round of testing, and 
ChAd3-EBO-Z was the vaccine selected on the basis of 
diﬀ erent criteria, which were an acceptable safety 
proﬁ le, induction of appropriate immune responses in 
human beings, protection of NHPs, and the timely 
availability of suﬃ  cient vaccine doses. However, 
evidence of eﬃ  cacy noted with VSV-ZEBOV in the ﬁ eld 
trial in Guinea led the DSMB for that trial to decline a 
switch to assessment of ChAd3-EBO-Z vaccine in the 
same study design of immediate versus delayed ring 
vaccination of contacts surrounding cases and instead 
to continue ring vaccination with VSV-ZEBOV, but only 
with use of immediate ring vaccination after con-
ﬁ rmation of cases; the delayed ring vaccinations that 
provided the comparator to estimate vaccine eﬃ  cacy 
were discontinued. Thus, the eﬃ  cacy trial transitioned 
to an assessment of the practicality and logistics of 
immediate ring vaccination as a control measure used 
in a west African setting. Indeed, since that DSMB 
decision, too few cases of Ebola have been conﬁ rmed in 
Guinea to have an eﬃ  cacy evaluation and, in mid-
September, 2015, Guinea had the ﬁ rst Ebola-free week 
since the previous 12 months.24
The timeframe in which the ChAd3-EBO-Z vaccine 
progressed from preclinical status to a phase 1b trial in 
Mali was astoundingly short. Ethics committees and the 
DSMB did their reviews and regulatory authorities 
arranged vaccine importations rapidly. The ﬁ rst 
vaccination occurred on Oct 8, 2014 (less than 2 months 
after the consortium assembled), the last participant was 
vaccinated on Nov 26, 2014, and the last day 28 blood was 
drawn on Dec 24, 2014. This short timeframe included 
obtaining of approvals for several changes in the size and 
design of the trial as further doses of vaccine became 
available.
MVA-BN-Filo booster vaccine given 11–16 weeks after 
priming with ChAd3-EBO-Z was well tolerated and 
powerfully immunogenic in elicitation of both 
anamnestic antibody responses and robust multi-
functional CD4 and CD8 memory T-cell responses. On 
the basis of data from NHP challenges,9 ChAd3-EBO-Z 
prime followed by boost with MVA encoding Zaire Ebola 
virus glycoprotein would be the preferred regimen for 
immunisation of front-line workers who need long-lived, 
high-level protection against repetitive exposures. 
Nevertheless, complexities exist from the perspective of 
immunisation programmes in procural and delivery of a 
two-dose schedule with two diﬀ erent vaccines.
This study has limitations. Like other phase 1 trials of 
Ebola vaccines in Africa,21,25 our study had an under-
representation of women. Also, our study would have 
been improved if more Malian participants could have 
received the 1 × 10¹¹ pu dose of ChAd3-EBO-Z than the 
number that did receive that dose in this study, had more 
doses been available. Similarly, the small number of 
doses of MVA-BN-Filo available limited the size of the 
nested booster study. Finally, our absence of access to a 
monovalent MVA expressing only Zaire Ebola virus 
glycoprotein prevented us from also studying that 
product in the booster study.
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